Raising money for a great cause!

  • HOME
  • ABOUT
  • MISSION
  • EVENT
  • KRB GIVING
  • CONTACT
  • Past Events
  • KWAC STORE
  • More
    • HOME
    • ABOUT
    • MISSION
    • EVENT
    • KRB GIVING
    • CONTACT
    • Past Events
    • KWAC STORE
  • HOME
  • ABOUT
  • MISSION
  • EVENT
  • KRB GIVING
  • CONTACT
  • Past Events
  • KWAC STORE

july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER

july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER

VOLUNTEER-LED 501(C)3 NON-PROFIT 

FOUNDATION TO FIGHT PEDIATRIC 

CANCER WITH A FOCUS ON 

EWING'S SARCOMA 



PURCHASE TICKETS & SPONSORSHIPs FOR 2025 EVENT
Donate Now!

july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER

july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER july 25, 2025 5TH ANNUAL KEVIN WANTS A CURE FUNDRAISER

VOLUNTEER-LED 501(C)3 NON-PROFIT 

FOUNDATION TO FIGHT PEDIATRIC 

CANCER WITH A FOCUS ON 

EWING'S SARCOMA 



PURCHASE TICKETS & SPONSORSHIPs FOR 2025 EVENT
Donate Now!

2024 EVENT SPONSORS

2025 EVENT SPONSORS

STATISTICS

Government Funding for Pediatric Cancer

Less than 4% of the NCI (National Cancer Institute) budget goes towards pediatric cancer research.

Ewing's Sarcoma Diagnosis Frequency

Approximately 200 kids per year in the U.S.A. are diagnosed with 

Ewing's Sarcoma.

Survival Rate for Metastasized Cases of Ewing's Sarcoma

 If the cancer has metastasized (spread to other parts of the body), the five-year survival rate is approximately 15-30%. 

WHY DO WE NEED TO RAISE MONEY?

 Limited Treatment Options: Despite improvements in treatment outcomes, current therapies for Ewing's sarcoma are often aggressive and can have significant side effects. There is a need for more targeted and effective treatments that can improve survival rates while minimizing long-term complications.


Drug Development: Funding is needed to support the development of new drugs and therapies specifically designed to treat Ewing's sarcoma. This includes preclinical research to identify promising drug candidates and clinical trials to evaluate their safety and efficacy in patients.


Improving Diagnosis and Prognosis: Research efforts can also focus on improving methods for diagnosing Ewing's sarcoma at an early stage and predicting patient outcomes. This can lead to better risk stratification and treatment planning, ultimately improving survival rates and quality of life for patients.


Supporting Clinical Trials: Clinical trials are essential for testing new treatments and advancing the standard of care for Ewing's sarcoma patients. However, conducting clinical trials requires significant resources, including funding for patient recruitment, treatment, and follow-up.


Overall, raising money for Ewing's sarcoma research is critical for advancing our understanding of the disease, developing more effective treatments, and ultimately improving outcomes for patients affected by this rare cancer.

 

clinical trials

Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma

Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma

Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma

https://www.mayo.edu/research/clinical-trials/cls-20442764

A Phase 1 Study of Lurbinectedin in Children With Solid Tumors

Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma

Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma

 https://www.mskcc.org/cancer-care/clinical-trials/23-053

A Phase II Study of LY2880070 and Gemcitabine in People with Ewing Sarcoma or Ewing-Like Sarcoma

Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma

A Phase II Study of LY2880070 and Gemcitabine in People with Ewing Sarcoma or Ewing-Like Sarcoma

https://www.mskcc.org/cancer-care/clinical-trials/21-428

where will your donation go?

DONATIONS WILL BE SENT TO FUND THIS TRIALGENERAL IMMUNOTHERAPY PAGE

Copyright © 2024 Kevin Boeckenhauer Family Foundation a 501(c)3 organization  - All Rights Reserved.

Powered by

  • HOME
  • ABOUT
  • MISSION
  • KRB GIVING
  • CONTACT
  • Privacy Policy

NEW 2025 LOCATION: EAGLEWOOD RESORT & SPA,   IN ITASCA, ILLINOIS!


Single Golfer - $200 Includes 18 holes of golf with cart, lunch, 2 drink tickets, and dinner. 


Foursome - $800  Includes 18 holes of golf with cart, lunch, 

2 drink tickets, and dinner for all four golfers. 


Dinner Only - $75.00 per person Includes 

(2) drink tickets and dinner. 

EVENT, GOLF AND SPONSORSHIP TICKETS HERE

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept